Illumina advances personalized cancer care with new pharma development partnerships

Illumina advances personalized cancer care with new pharma development partnerships

Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker

Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina's commitment to advance access for patients to precision oncology care by generating standardized, globally distributable tests. The new companion diagnostic partnerships will focus on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.

"Developing companion diagnostic claims for the historically important KRAS biomarker will enable broader identification of patients who may benefit from targeted therapies, regardless of tumor origin," said Traci Pawlowski , vice president and head of Clinical Solutions at Illumina. "This marks a critical step forward as we build our clinical offerings to support clinicians and pharmaceutical partners in delivering more personalized, effective, and broadly accessible precision cancer care."

Genomic profiling with CDx helps match patients to precision therapies

CDx built on TSO Comprehensive help clinicians match patients with approved targeted therapies based on the genetic mutations underlying their cancer. TSO Comprehensive does this by generating a molecular tumor profile that can identify the genetic mutations driving cancer growth. To target those underlying mutations, clinicians use the CDx to confirm whether a patient is a candidate for a targeted therapy or clinical trial.

KRAS is one of the most commonly mutated oncogenes in cancer, driving tumor proliferation, survival, and progression. Given its prominence in cellular transformation, previous research has demonstrated that identifying KRAS variants is critical for proper therapy selection and improving patient outcomes. 1,2

Genomics paves the way in precision oncology

Recent advances using genomics to detect KRAS variants have been successfully demonstrated across cancer types despite historical challenges in targeting KRAS . This includes traditionally difficult-to-treat diseases like pancreatic ductal adenocarcinoma, leading to opportunities for improved prognostication and treatment decisions. 1,2 Genomics insights into KRAS both enhance our understanding of KRAS -driven tumor biology and pave the way for more personalized therapeutic strategies.

" KRAS mutations are common across cancer types but have historically been difficult to address," said Kashif Firozvi , MD, Maryland Oncology Hematology. "The field is evolving rapidly, with new therapies better suited to patients with mutations in this once 'undruggable' gene. As the treatment landscape expands, including drugs that target the KRAS pathway, knowing a patient's KRAS status becomes essential to guiding effective treatment protocols and improving outcomes."

Illumina maintains a growing pipeline of CDx claims under development through partnerships with pharmaceutical companies, which will continue to support groundbreaking targeted therapies and immunotherapies to make a difference in the lives of patients with cancer.

To learn more about TruSight Oncology Comprehensive, click here .

References:

  1. Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends in Cancer . 2025;11(2): 91-116. doi:10.1016/j.trecan.2024.11.009
  2. Fakih MM. KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. Clinical Colorectal Cancer . 2010;9(1): 22-30. doi:10.3816/CCC.2010.n.003

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; (iii) legislative, regulatory and economic developments; (iv) our ability to manufacture robust instrumentation and consumables; (iv) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X , Facebook , LinkedIn , Instagram , TikTok , and YouTube .

Contacts

Investors:
Brian Blanchett
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/illumina-advances-personalized-cancer-care-with-new-pharma-development-partnerships-302564027.html

SOURCE Illumina, Inc.

News Provided by PR Newswire via QuoteMedia

ILMN
The Conversation (0)
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24 to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market... Keep Reading...
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS ™ into all reagents for its NextSeq ™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. "We are excited... Keep Reading...
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

"When-issued" trading expected to begin on or about June 12, 2024 Record date for distribution of GRAIL shares will be June 13, 2024 Distribution date for GRAIL shares anticipated to be June 24, 2024 Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the... Keep Reading...
Illumina appoints Everett Cunningham Chief Commercial Officer

Illumina appoints Everett Cunningham Chief Commercial Officer

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of... Keep Reading...
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based... Keep Reading...

Latest Press Releases

Related News